Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
India · Delayed Price · Currency is INR | Market Cap | 1.20T +27.3% |
| Revenue (ttm) | 303.78B +24.0% |
| Net Income | 41.98B -14.7% |
| EPS | 41.83 -14.5% |
| Shares Out | 997.50M |
| PE Ratio | 28.83 |
| Forward PE | 26.90 |
| Dividend | 1.00 (0.08%) |
| Ex-Dividend Date | Jul 24, 2026 |
| Volume | 1,992,866 |
| Open | 1,199.40 |
| Previous Close | 1,199.50 |
| Day's Range | 1,193.90 - 1,209.20 |
| 52-Week Range | 835.50 - 1,266.60 |
| Beta | 0.31 |
| Analysts | Hold |
| Price Target | 1,238.40 (+2.69%) |
| Earnings Date | Nov 4, 2026 |
About Zydus Lifesciences
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Consumer Products, and Medical Technologies. The company offers active pharmaceutical ingredients, human and finished dosage formulations, generics, branded generics, specialty formulations, biosimilars, vaccines, novel therapeutics, medical devices and technologies, consumer wellness, veterinary, an... [Read more]
Financial Performance
In fiscal year 2026, Zydus Lifesciences's revenue was 271.48 billion, an increase of 16.81% compared to the previous year's 232.42 billion. Earnings were 50.40 billion, an increase of 11.37%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for ZYDUSLIFE stock is "Hold." The 12-month stock price target is ₹1,238, which is an increase of 2.69% from the latest price.
News
Zydus Lifesciences Q2 net profit drops 27% despite 29% revenue growth
Zydus Lifesciences Q2 FY27 net profit fell 27% to Rs 925.5 crore despite 29% revenue growth to Rs 7,909.6 crore; EBITDA down 6%, margin 24%.
Zydus Lifesciences Transcript: Q2 26/27
Q2 revenue grew 29% YoY with 24% EBITDA margin, while branded and U.S. specialty businesses expanded. FY27 margin guidance is maintained; saroglitazar launch investment, regulatory timing and litigation remain key variables.
Zydus Lifesciences Quarterly report: Q2 2027
Zydus Lifesciences has published its Q2 2027 quarterly earnings report on November 4, 2026.
Zydus Lifesciences Slides: Q2 2027
Zydus Lifesciences has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 4, 2026.
India's Zydus Lifesciences posts lower profit as expenses outpace revenue growth
Indian drugmaker Zydus Lifesciences reported a 26.6% fall in second-quarter profit on Wednesday, as rising expenses outweighed stronger demand, pushing its shares about 4% lower.
USFDA accepts biosimilar application of Zydus and German firm for Keytruda
NEW DELHI: Zydus Lifesciences and Formycon AG, an independent developer of biosimilars, jointly announced that the US Food and Drug Administration (USFDA)
FDA Accepts BLA For Formycon And Zydus' Keytruda Biosimilar FYB206 ;Shares Rise
(RTTNews) - Formycon AG (FYB.DE), an independent developer of biosimilars, and Zydus Lifesciences Ltd., a life sciences company, jointly announced that the U.S. Food and Drug Administration (FDA) has ...
Zydus Lifesciences proposes ₹1,000cr university near Ahmedabad
Aims to build a strong academic and research ecosystem in life sciences
Mereo BioPharma Licenses Alvelestat Rights To Sentynl Therapeutics
(RTTNews) - Sentynl Therapeutics, Inc., a unit of Zydus Lifesciences Limited, on Tuesday said it has entered into an option and license agreement with Mereo BioPharma Group plc (MREO) for U.S. commerc...
Zydus Life Q1 PAT falls 36% to Rs 940 crore as revenue rises 22%
Zydus Lifesciences Q1 FY27: PAT down 36% to Rs 940 cr as revenue rose 22% to Rs 8,017 cr; margins fell; US biosimilar launch and Assertio buy.
Zydus Lifesciences Transcript: Q1 26/27
Q1 FY 2027 saw 22% revenue growth and a 24.1% EBITDA margin, driven by strong performance in India, international, and consumer wellness segments. Strategic acquisitions, innovation, and branded portfolio expansion are expected to boost margins and profitability in the medium term.
Zydus Lifesciences Quarterly report: Q1 2027
Zydus Lifesciences has published its Q1 2027 quarterly earnings report on August 11, 2026.
Zydus Lifesciences Slides: Q1 2027
Zydus Lifesciences has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 11, 2026.
Zydus Lifesciences Slides: Corporate presentation
Zydus Lifesciences has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Zydus gets approval for Phase III trial of sickle cell disease drug
Zydus Lifesciences wins approval for Phase III Desidustat trial in sickle cell disease, with ICMR; 164 patients, 203 days, placebo-controlled.
Zydus Lifesciences extends API business acquisition deadline to September 2026
Zydus Lifesciences has announced an extension of the closing date for its acquisition of the API business from Sterling Biotech Limited (SBL). The transaction, initially expected to complete by Decemb...
Zydus Lifesciences invests USD 5 million in joint venture with Sunshine Healthcare
Zydus Lifesciences Limited has entered into a Share Subscription and Shareholders’ Agreement with Sunshine Healthcare Lanka Limited to acquire 50% of the equity share capital of Zydus Sunshine Lifesci...
Zydus Lifesciences sees significant buyback participation from promoters
Zydus Lifesciences Limited has disclosed substantial participation in its equity share buyback programme by its promoters and promoter group. The buyback involved equity shares of Re. 1 each, accepted...
Zydus Lifesciences completes Rs 1,100 crore buyback extinguishing over 87 lakh shares
Zydus Lifesciences Limited has successfully completed a buyback of 87,30,158 equity shares, each with a face value of ₹1, at a price of ₹1,260 per share. The total buyback size…
Top stocks for trade today, June 17: Infosys, Wipro, TCS, Zydus Lifesciences, Bharat Forge and more
Several stocks are expected to remain in focus on June 17 following key corporate announcements, strategic partnerships, acquisitions, buybacks, management changes, fundraising activities, and regulat...
Zydus Lifesciences completes merger with Assero Holdings for USD 166.33 million
Zydus Lifesciences Limited has successfully completed the merger of its acquisition subsidiary, Zara Merger Sub Inc., with Assero Holdings Inc., making Assero a wholly owned subsidiary of the company....
Zydus completes acquisition of Assertio Holdings for $23.50 per share
Zydus Lifesciences Ltd. has successfully completed the acquisition of Assertio Holdings, Inc. through a cash tender offer. The purchase was executed via Zydus's wholly-owned subsidiary, Zara Merger Su...
Zydus Lifesciences reports significant reduction in GST demand for subsidiary
Zydus Lifesciences Limited has announced a favourable outcome in the Goods and Services Tax (GST) demand case involving its wholly owned subsidiary, Zydus Healthcare Limited (ZHL). The Appellate Addit...
Zydus Lifesciences receives USFDA warning letter for Baddi manufacturing facility
Zydus Lifesciences has informed stock exchanges that it has received a Warning Letter from the United States Food and Drug Administration (USFDA) concerning its formulation manufacturing facility loca...
Pharma sector stocks today, June 3: Natco Pharma falls 2.57%, Zydus Lifesciences falls 1.26%, Alembic Pharma down 1.06%
Pharmaceutical stocks traded mixed on June 3, 2026, during the morning session. While a few stocks posted modest gains, several others witnessed selling pressure. The BSE Healthcare index declined 0.2...